Investing carries serious risks, including partial or total loss of capital. Please read the Information Note and the Risk factors and login before investing.

Cole Pharmaceuticals 1A

Sustainable Development Tax Shelter
Equity Belgium 118 investors
Improving peoples' lives by redefining Vitamin D treatments
Information Note Terms & Conditions
€1,100,000
Pre money valuation
33.7%
Equity offered
€156,900
Amount raised
€225,000
Committed by co-investors
3 days
Remaining
€50,000
Minimum target
314% funded

Claude Lubicki

Co-founder

Claude Lubicki (French), the CEO, over 30 years of pharmaceutical and biotech industry experience and consulting. Prior to co-founding Cole Pharmaceuticals, Claude Lubicki was most recently, the business development representative in Europe of Endoceutics, a Canadian bio-pharmaceutical company. In this role, he successfully closed seven out-licensing deals. In his wealth of international experience, Claude Lubicki has held senior positions in pharmaceutical companies such as GSK, Orion Pharma, Menarini, Grünenthal spanning General Management, Business Development, Global Marketing. His experience covers a wide array of therapeutic areas.

Jean-Marie Vandeplas

Co-founder

Jean-Marie Vandeplas (Belgian), the Chief Commercial Officer, has over 30 years of experience in pharmaceutical companies in various sales and marketing positions. He has an extensive experience in Women’s Health Care including osteoporosis and vitamin D. Jean-Marie Vandeplas began his career at Organon. Today, Jean-Marie Vandeplas works as a consultant in the pharmaceutical industry. He has completed several missions in Marketing Strategy and Business Development for companies such as Wyeth, Merck KGAA, Johnson & Johnson, Will-Pharma, Mithra Pharmaceuticals, Besins HealthCare, Novadip.

Christian Huyghe

CTO

Christian Huyghe (Belgium), a doctor by training and is the acting Chief Scientific Officer. Christian has over 25 years of experience in the pharmaceutical industry and is also a recognized Market Access consultant. He has worked for companies such as Organon, Wyeth, Servier and Sanofi.

TAX SHELTER 45%

This business qualifies for the startup tax shelter. If you meet the conditions, 45% of your investment will be reducted from your personal income taxes. Read more…
Please note €101,200 remains available for Tax Shelter investments.